uniQure N.V.QURE stock score: 45/100
$20.23 · -0.34% · Scored Nov 19, 2026
- Technical
- 29
- Fundamental
- 49
- News
- 54
The reading
uniQure (QURE) scores 45 out of 100, which reads weak, higher than 34% of Healthcare stocks and 32% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 49, technicals 29.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 15 and contrarian oscillators 67 — a split worth reading before trusting the technical total.
News sentiment is neutral at 54; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 35 to 55, and it is down 9 points over the period.
About uniQure
uniQure (QURE) is a Netherlands-based gene therapy company that develops one-time treatments delivered with adeno-associated virus vectors. Its main program is AMT-130, an investigational therapy for Huntington’s disease that is infused directly into the brain and is designed to reduce production of the harmful huntingtin protein. Its clinical results have been measured against an external control group of untreated patients rather than a placebo arm, and whether regulators accept that comparison is central to its path to approval. The company developed Hemgenix, a gene therapy for hemophilia B that CSL Behring sells under license, and it has sold part of its royalty interest in that product to a royalty investor. It earns limited revenue today, mainly from royalties and collaboration income, and funds research largely through stock offerings and its cash reserves.
uniQure competes with Roche, Novartis, Wave Life Sciences and other companies developing drugs that lower huntingtin levels, as well as with gene therapy developers in its other disease areas. Its edge rests on years of patient follow-up with AMT-130, experience manufacturing viral vectors and expertise in delivering gene therapy to the brain. Investors who follow QURE stock tend to watch the regulatory path for AMT-130 in the United States and Europe. Updated trial data and the reliability of the external comparison are closely followed. Cash runway and launch preparations are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward QURE’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
49Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
EV/Revenue compares the whole company's value, debt included, with its sales.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
22Pulling it up
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.
Holding it back
SMA 50 Trend evaluates the slope of the 50-period moving average.
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 54
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 32 | 1 |
| Daily | 22 | 3 |
| Weekly | 27 | 2 |
| Monthly | 42 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 45 |
| Nov 18, 2026 | 45 |
| Nov 17, 2026 | 45 |
| Nov 16, 2026 | 45 |
| Nov 15, 2026 | 47 |
| Nov 14, 2026 | 47 |
| Nov 13, 2026 | 47 |
| Nov 12, 2026 | 46 |
| Nov 11, 2026 | 42 |
| Nov 10, 2026 | 39 |
| Nov 8, 2026 | 37 |
| Nov 7, 2026 | 37 |
| Nov 6, 2026 | 37 |
| Nov 5, 2026 | 36 |
| Nov 4, 2026 | 40 |
| Nov 3, 2026 | 41 |
| Nov 2, 2026 | 42 |
| Nov 1, 2026 | 43 |
| Oct 31, 2026 | 43 |
| Oct 30, 2026 | 42 |
| Oct 29, 2026 | 42 |
| Oct 28, 2026 | 41 |
| Oct 27, 2026 | 40 |
| Oct 26, 2026 | 36 |
| Oct 25, 2026 | 38 |
| Oct 24, 2026 | 38 |
| Oct 23, 2026 | 38 |
| Oct 22, 2026 | 39 |
| Oct 21, 2026 | 38 |
| Oct 20, 2026 | 38 |
| Oct 19, 2026 | 38 |
| Oct 18, 2026 | 37 |
| Oct 17, 2026 | 37 |
| Oct 16, 2026 | 36 |
| Oct 15, 2026 | 37 |
| Oct 14, 2026 | 35 |
| Oct 13, 2026 | 35 |
| Oct 12, 2026 | 35 |
| Oct 11, 2026 | 37 |
| Oct 10, 2026 | 37 |
| Oct 9, 2026 | 37 |
| Oct 8, 2026 | 37 |
| Oct 7, 2026 | 38 |
| Oct 6, 2026 | 37 |
| Oct 5, 2026 | 37 |
| Oct 4, 2026 | 37 |
| Oct 3, 2026 | 37 |
| Oct 2, 2026 | 38 |
| Oct 1, 2026 | 37 |
| Sep 30, 2026 | 38 |
| Sep 29, 2026 | 38 |
| Sep 28, 2026 | 45 |
| Sep 27, 2026 | 45 |
| Sep 26, 2026 | 45 |
| Sep 25, 2026 | 45 |
| Sep 24, 2026 | 46 |
| Sep 23, 2026 | 49 |
| Sep 22, 2026 | 53 |
| Sep 21, 2026 | 51 |
| Sep 20, 2026 | 51 |
| Sep 19, 2026 | 51 |
| Sep 18, 2026 | 50 |
| Sep 17, 2026 | 51 |
| Sep 16, 2026 | 48 |
| Sep 15, 2026 | 49 |
| Sep 14, 2026 | 51 |
| Sep 13, 2026 | 51 |
| Sep 12, 2026 | 51 |
| Sep 11, 2026 | 51 |
| Sep 10, 2026 | 50 |
| Sep 9, 2026 | 52 |
| Sep 8, 2026 | 53 |
| Sep 7, 2026 | 51 |
| Sep 6, 2026 | 51 |
| Sep 5, 2026 | 51 |
| Sep 4, 2026 | 51 |
| Sep 3, 2026 | 52 |
| Sep 2, 2026 | 52 |
| Sep 1, 2026 | 53 |
| Aug 31, 2026 | 52 |
| Aug 30, 2026 | 54 |
| Aug 29, 2026 | 54 |
| Aug 28, 2026 | 53 |
| Aug 27, 2026 | 54 |
| Aug 26, 2026 | 54 |
| Aug 25, 2026 | 55 |
| Aug 24, 2026 | 53 |
| Aug 23, 2026 | 54 |
| Aug 22, 2026 | 54 |
Key facts
- Market cap
- $1.4B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.13
- Risk grade (1–10)
- 3
- Next earnings
- Nov 4, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| MESO Mesoblast | $1.5B | 49 |
| ABSI Absci | $1.4B | 27 |
| ANAB AnaptysBio | $1.4B | 69 |
| RAPP Rapport Therapeutics | $1.4B | 32 |
| NBTX Nanobiotix | $1.4B | 48 |
| IMCR Immunocore Holdings | $1.4B | 51 |
Questions
What is QURE's stock rating today?
QURE scores 45/100 (Weak) as of Nov 19, 2026: technical 29, fundamental 49, and news sentiment 54, which is shown but not counted. Scores are recomputed every night.
What does uniQure do?
uniQure (QURE) is a Netherlands-based gene therapy company that develops one-time treatments delivered with adeno-associated virus vectors. Its main program is AMT-130, an investigational therapy for Huntington’s disease that is infused directly into the brain and is designed to reduce production of the harmful huntingtin protein.
Is QURE stock a buy?
The score is not a buy or sell recommendation. A 45 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the QURE score calculated?
99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/qure/"><img src="https://stocksscores.com/stocks/qure/badge.svg" alt="QURE stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/qure/)